NTRK1 and non-small cell lung carcinoma: In that study, a partitioned survival model was developed to compare differences in expected life-years and quality-adjusted life-years for larotrectinib versus entrectinib in the second line of therapy for TRK fusion-positive metastatic non-small cell lung cancer [16].